dopamine antagonists

Preferred Label : dopamine antagonists;

MeSH definition : Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME.;

MeSH synonym : antagonists, dopamine receptor; receptor antagonists, dopamine; dopaminergic antagonists; dopamine blockers; blockers, dopamine; dopamine receptor antagonists; antagonists, dopamine; antagonists, dopaminergic; Dopamine Blocker; Blocker, Dopamine; Dopamine Receptor Antagonist; Antagonist, Dopamine Receptor; Receptor Antagonist, Dopamine; Dopaminergic Antagonist; Antagonist, Dopaminergic; Dopamine Antagonist; Antagonist, Dopamine;

MeSH annotation : DF: DOPAMINE ANTAG;

Wikipedia link : https://en.wikipedia.org/wiki/Dopamine antagonist;

Is substance : O;

action pharmacologique : O;

Details

Origin ID

D018492;

UMLS CUI

C0242702;

Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- analysis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- Dopamine receptor antagonist (disposition) [SNOMED CT concept]
- Human Anti-Idiotype Antibody [NCIt concept]
- Substance with dopamine receptor antagonist mechanism of action (substance) [SNOMED CT concept]
Currated CISMeF NLP mapping
- Dopamine Antagonist [NCIt concept]
Indexing information
- ABT-925 [MeSH Supplementary Concept]
- NGB 2904 [MeSH Supplementary Concept]
- clebopride [MeSH Supplementary Concept]
MeSH Descriptor(s) used for indexing
- dopamine [MeSH Descriptor]
- receptors, dopamine [MeSH Descriptor]
Record concept(s)
- dopamine antagonists [MeSH concept]
See also
- antipsychotic agents [MeSH Descriptor]
See also (suggested by CISMeF)
- receptors, dopamine [MeSH Descriptor]
Semantic type(s)
- Pharmacologic Substance [UMLS semantic type]
Substance(s)
- (5,6-dimethoxyindan-2-yl)dipropylamine [MeSH Supplementary Concept]
- 1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline [MeSH Supplementary Concept]
- 1-(2-ethoxyphenyl)-4-(3-(3-thiophen-2-ylisoxazolin-5-yl)propyl)piperazine [MeSH Supplementary Concept]
- 1-methyl-1,2,3,4-tetrahydroisoquinoline [MeSH Supplementary Concept]
- 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine [MeSH Supplementary Concept]
- 1H-3-benzazepin-7-ol, 8-bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl- [MeSH Supplementary Concept]
- 3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo(2,3-b)pyridine [MeSH Supplementary Concept]
- 3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-benzazepine [MeSH Supplementary Concept]
- 3-(4-(4-chlorophenyl)piperazinylmethyl)pyrazolo(1,5-a)pyridine [MeSH Supplementary Concept]
- 3-(4-(4-chlorophenyl-4-hydroxypiperidino)methyl)indole [MeSH Supplementary Concept]
- 3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide [MeSH Supplementary Concept]
- 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone [MeSH Supplementary Concept]
- 5-methoxy-1-methyl-2-(n-propylamino)tetralin [MeSH Supplementary Concept]
- 7-methyl-2,3-dimethoxy-5,6,7,8,9,14-hexahydrodibenz(d,g)azecine [MeSH Supplementary Concept]
- 7-methyl-6,7,8,9,14,15-hexahydro-5H-benz(d)indolo(2,3-g)azecine [MeSH Supplementary Concept]
- 8-iodo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepine-7-ol [MeSH Supplementary Concept]
- Amisulpride [MeSH Descriptor]
- CI 1030 [MeSH Supplementary Concept]
- CP 293019 [MeSH Supplementary Concept]
- EEDQ [MeSH Supplementary Concept]
- FAUC 346 [MeSH Supplementary Concept]
- FAUC 365 [MeSH Supplementary Concept]
- FLB 457 [MeSH Supplementary Concept]
- N-(2-((bis(4-fluorophenyl)methyl)thio)ethyl)-3-phenylpropan-1-amine [MeSH Supplementary Concept]
- NGB 2849 [MeSH Supplementary Concept]
- S 18126 [MeSH Supplementary Concept]
- S-phenylpiracetam [MeSH Supplementary Concept]
- UH 232 [MeSH Supplementary Concept]
- VK4-116 [MeSH Supplementary Concept]
- acepromazine [MeSH Descriptor]
- aceprometazine [MeSH Supplementary Concept]
- amoxapine [MeSH Descriptor]
- azaperone [MeSH Descriptor]
- benperidol [MeSH Descriptor]
- bromopride [MeSH Supplementary Concept]
- butaclamol [MeSH Descriptor]
- chlorpromazine [MeSH Descriptor]
- chlorprothixene [MeSH Descriptor]
- clopenthixol [MeSH Descriptor]
- domperidone [MeSH Descriptor]
- ecopipam [MeSH Supplementary Concept]
- eticlopride [MeSH Supplementary Concept]
- flupenthixol [MeSH Descriptor]
- flupenthixol decanoate [MeSH Supplementary Concept]
- fluphenazine [MeSH Descriptor]
- fluspirilene [MeSH Descriptor]
- haloperidol [MeSH Descriptor]
- loxapine [MeSH Descriptor]
- mesdopetam [MeSH Supplementary Concept]
- mesoridazine [MeSH Descriptor]
- methotrimeprazine [MeSH Descriptor]
- nafadotride [MeSH Supplementary Concept]
- nemonapride [MeSH Supplementary Concept]
- penfluridol [MeSH Descriptor]
- perazine [MeSH Descriptor]
- perphenazine [MeSH Descriptor]
- pimozide [MeSH Descriptor]
- prochlorperazine [MeSH Descriptor]
- promazine [MeSH Descriptor]
- raclopride [MeSH Descriptor]
- remoxipride [MeSH Descriptor]
- risperidone [MeSH Descriptor]
- spiperone [MeSH Descriptor]
- spiroxatrine [MeSH Supplementary Concept]
- stepholidine [MeSH Supplementary Concept]
- sulpiride [MeSH Descriptor]
- tetrahydropalmatine [MeSH Supplementary Concept]
- thiethylperazine [MeSH Descriptor]
- thioridazine [MeSH Descriptor]
- thiothixene [MeSH Descriptor]
- tiapride hydrochloride [MeSH Descriptor]
- trifluoperazine [MeSH Descriptor]
- trifluperidol [MeSH Descriptor]
- triflupromazine [MeSH Descriptor]
- ziprasidone [MeSH Supplementary Concept]
UMLS correspondences (same concept)
- Dopamine Antagonist [NCIt concept]
- Product containing dopamine receptor antagonist (product) [SNOMED CT concept]
- Substance with dopamine receptor antagonist mechanism of action (substance) [SNOMED CT concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients